Table of Content

1. Combination Cancer Immunotherapy – New Era in Cancer Research


2. Need for Combination Cancer Immunotherapy


3. Clinically & Commercially Approved Combination Cancer Immunotherapy


4. Global Combination Cancer Immunotherapy Market Size & Trend Analysis
4.1 Current Market Scenario
4.2 Future Market Opportunity


5. Global Combination Cancer Immunotherapy Market Size & Trend Analysis by Indication
5.1 Breast Cancer
5.2 Kidney Cancer
5.3 Lung Cancer
5.4 Liver Cancer
5.5 Gastric Cancer
5.6 Lymphoma
5.7 Prostate Cancer
5.8 Melanoma
5.9 Colorectal Cancer
5.10 Leukemia
5.11 Cervical Cancer
5.12 Pancreatic Cancer
5.13 Ovarian Cancer
5.14 Head & Neck Cancer
5.15 Multiple Myeloma


6. Global Combination Cancer Immunotherapy Market Size & Trend Analysis by Region
6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 Australia
6.6 South Korea
6.7 Canada
6.8 UK


7. Approved Immune Checkpoint Inhibitor In Combination Cancer Immunotherapy – Clinical & Commercial Insights
7.1 Patent, Price & Dosage Analysis
7.2 Global & Regional Sales Insights


8. Approved Antibody Drug Conjugate In Combination Cancer Immunotherapy – Clinical & Commercial Insights
8.1 Patent, Price & Dosage Analysis
8.2 Global & Regional Sales Insights


9. Approved Monoclonal Antibodies In Combination Cancer Immunotherapy – Clinical & Commercial Insights
9.1 Patent, Price & Dosage Analysis
9.2 Global & Regional Sales Insights


10. Combination Cancer Immunotherapy Clinical Trials Overview
10.1 By Company
10.2 By Country
10.3 By Patient Segment/Disease Stage
10.4 By Phase


11. Combination Cancer Immunotherapy Clinical Trials & Patent Insight By Company, Country, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered


12. Marketed Combination Cancer Immunotherapy Clinical & Patent Insight By Company, Country, & Indication


13. Combination Strategies to Enhance Immune Checkpoint Inhibitors Efficacy
13.1 In Combination with Other Immune Checkpoint Blockade:
13.2 Ongoing Clinical Trials of ICI with Conventional Therapies; Chemotherapy &
Radiation
13.3 ICI Trials with Other Targeted Therapies
13.4 Recent Trends in Market: Partnerships, Collaboration, & Investments


14. Combination of Therapeutic Antibodies in Clinical Oncology
14.1 Combination Trials of Monoclonal Antibodies
14.2 Clinical Trials of Bispecific Antibody Combination Therapy
14.3 Pharmaceutical Investments Boosting Market



15. Engaging Cancer Vaccines in Combination Therapy
15.1 Preclinical Studies Evaluating Vaccines in Combination Therapy
15.2 Clinical Trials Evaluating Cancer Vaccines in Combination Approach
15.3 Ongoing Research Agreement & Collaboration


16. Antibody Drug Conjugate in Combination Therapy
16.1 Ongoing Clinical Investigations
16.2 Pharmaceutical Collaborations & Supply Agreements


17. Combination Therapy with CAR T Cell Therapy
17.1 Preclinical Studies Combining CAR T cell Therapy
17.2 Clinical Trials Evaluating Combination Therapies with CAR T Cells
17.3 Ongoing Research & Development Activities


18. Oncolytic Virus Combination Therapy
18.1 OV Combination Immunotherapy
18.2 Oncolytic Virus in Combination with Other Regimens
18.3 Recent Trends in Market: Partnerships, Collaboration, & Investments


19. Competitive Landscape
19.1 AbbVie
19.2 Agenus
19.3 Akeso Pharmaceutical
19.4 Amgen
19.5 Arbutus Biopharma
19.6 AstraZeneca
19.7 AUM Bioscience
19.8 BeiGene
19.9 BioNTech
19.10 Bristol Myers Squibb
19.11 Candel Therapeutics
19.12 Eli Lilly
19.13 Elicio Therapeutics
19.14 Fate Therapeutics
19.15 GlaxoSmithKline
19.16 Harpoon Therapeutics
19.17 Immutep
19.18 Imugene
19.19 Intensity Therapeutics
19.20 Janssen Pharmaceuticals
19.21 Merck
19.22 MorphoSys
19.23 Novocure
19.24 Novartis
19.25 Nykode Therapeutics
19.26 Ono Pharmaceutical
19.27 Oxford Biotherapeutics
19.28 Pfizer
19.29 Regeneron?
19.30 Roche
19.31 Sanofi
19.32 Seagen
19.33 Shanghai Junshi Biosciences
19.34 Takeda Pharmaceuticals
19.35 Qurient

 



List of Tables

Table 2-1: Advantages of Immunotherapy & their Combinations
Table 3-1: Global – Approval Combination Cancer Immunotherapy by Indication
Table 13-1: Ongoing Clinical Trial in Immune Checkpoint Inhibitor Combination Therapy
Table 13-2: ICI Combination Therapy with Chemotherapy in Preclinical Models
Table 13-3: Ongoing Clinical Trials in ICI Combined with Targeted Therapies
Table 14-1: Ongoing Clinical Trials in Monoclonal Antibody Combination Therapies
Table 14-2: Ongoing Clinical Trials in Bispecific Antibody Combination Therapies
Table 15-1: Ongoing Clinical Studies Evaluating Vaccines in Combination Therapy
Table 16-1: Ongoing Clinical Studies Evaluating Antibody Drug Conjugate in Combination Therapy
Table 17-1: Preclinical Studies Combining CAR T Cells with Oncolytic Virus
Table 17-2: Ongoing & Completed Clinical Trials Testing Combination Therapies with CAR T Cells
Table 18-1: Current Clinical Trials of Combination Therapy with OVs and Immune Checkpoint Inhibitors
Table 18-2: Mechanism of Synergy of Chemotherapy & Oncolytics Virus Combination